Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy.

NCT05964257 is registered in ClinicalTrials.gov with Huons Biopharma as lead sponsor.

NCT NCT05964257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05964257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy.
Lead sponsor
Huons Biopharma
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 25, 2023
Completion date
May 30, 2025
Enrollment
188 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign masseteric hypertrophy